Archives
PP2A-Driven Autophagy Fuels Drug Resistance in C. albicans B
2026-04-13
PP2A-Driven Autophagy Fuels Drug Resistance in Candida albicans Biofilms
Study Background and Research Question
Candida albicans is a prominent opportunistic fungal pathogen, frequently implicated in oral, gastrointestinal, and systemic infections, particularly in immunocompromised individuals. A major challenge in treating C. albicans infections arises from the organism’s ability to form robust biofilms—structured microbial communities that exhibit high resistance to conventional antifungal agents. The mechanisms underlying this biofilm-associated resistance remain incompletely understood, impeding the development of effective therapeutic interventions [source_type: paper][source_link: https://doi.org/10.1016/j.identj.2025.103873]. A growing body of evidence points to fungal autophagy as a key adaptive process influencing biofilm maturation and stress tolerance. Protein phosphatase 2A (PP2A), a fundamental Ser/Thr phosphatase, regulates numerous physiological pathways, but its specific role in fungal autophagy and drug resistance has not been fully elucidated in C. albicans.Key Innovation from the Reference Study
The referenced study by Shen et al. [source_type: paper][source_link: https://doi.org/10.1016/j.identj.2025.103873] provides a mechanistic advance: it demonstrates that PP2A modulates drug resistance in C. albicans biofilms by regulating autophagy via ATG protein phosphorylation. Specifically, PP2A-driven phosphorylation of Atg13 leads to the activation of Atg1, triggering autophagic flux that contributes to both biofilm formation and increased antifungal resistance.Methods and Experimental Design Insights
The investigators used a comprehensive strategy combining genetic, biochemical, and in vivo approaches:- Construction of a PP2A catalytic subunit knockout mutant (pph21Δ/Δ) in C. albicans, compared to wild-type controls.
- Assessment of biofilm development, drug susceptibility, and oxidative stress, both in standard and autophagy-activated (via rapamycin) conditions.
- Measurement of autophagic activity through detection of autophagosomes and quantification of Atg1/Atg13 protein levels.
- Evaluation of antifungal treatment efficacy in a murine model of oral C. albicans infection [source_type: paper][source_link: https://doi.org/10.1016/j.identj.2025.103873].
Core Findings and Why They Matter
The study established several critical points:- PP2A is essential for autophagy induction: The loss of PPH21 reduced Atg13 and Atg1 levels, impairing autophagy even under rapamycin stimulation.
- Autophagy activation fuels biofilm resistance: Pharmacological induction of autophagy increased drug resistance and biofilm biomass, but these effects were blunted in pph21Δ/Δ mutants.
- PP2A deficiency enhances antifungal efficacy in vivo: Mice infected with pph21Δ/Δ C. albicans responded better to antifungal agents than those infected with wild-type strains, underscoring PP2A’s central role in drug resistance [source_type: paper][source_link: https://doi.org/10.1016/j.identj.2025.103873].
- Oxidative stress adaptation: PP2A-deficient strains exhibited reduced capacity to handle oxidative stress, linking autophagy to stress resilience in biofilms.
Protocol Parameters
- biofilm antifungal susceptibility assay | 1–4 μg/mL Amphotericin B | cell-based C. albicans biofilm | Standard range for evaluating drug resistance using polyene antifungal antibiotic | workflow_recommendation
- autophagy induction (rapamycin) | 100 nM | C. albicans biofilm and planktonic cells | Established concentration for robust autophagy stimulation | paper [source_type: paper][source_link: https://doi.org/10.1016/j.identj.2025.103873]
- Amphotericin B solubility test | ≥46.2 mg/mL in DMSO | compound stock preparation | Ensures complete solubilization for dosing accuracy | product_spec [source_type: product_spec][source_link: https://www.apexbt.com/amphotericin-b.html]
Comparison with Existing Internal Articles
Several internal resources contextualize these findings within broader antifungal drug research:- "Amphotericin B at the Nexus of Mechanism and Innovation" discusses how mechanistic advances, such as PP2A-mediated autophagy, inform the use of polyene antifungal antibiotics in resistant biofilm models. This aligns with Shen et al.’s demonstration that autophagy is a modifiable axis for drug resistance.
- "Amphotericin B: Polyene Antifungal Antibiotic for Fungal Biofilm Research" details the sterol-targeting mechanism of Amphotericin B, which directly relates to overcoming fungal membrane adaptations seen in biofilm-associated resistance and supports the practical use of validated concentration ranges [source_type: workflow_recommendation][source_link: https://amyloid-peptide-25-35-human.com/index.php?g=Wap&m=Article&a=detail&id=15677].
Limitations and Transferability
While the study robustly connects PP2A and autophagy to drug resistance in C. albicans biofilms, several considerations remain:- The use of a murine oral infection model supports translational potential but may not fully capture the complexity of human mucosal or systemic candidiasis.
- Rapamycin-mediated autophagy induction is a pharmacological model; physiological triggers of autophagy in clinical biofilms can be more heterogeneous.
- The focus on a single phosphatase (PP2A) does not exclude roles for other signaling pathways in biofilm regulation and antifungal resistance.